|
195. Li, Y.; Mori, W.; Chaudhary, A.; Zhao, C.; Yamasaki, T.; Zhang, Z.; Feng, S.; Ware, T.; Rong, J.; Fujinaga, M.; Chen, J.; Kumata, K.; Zhang, Y.; Hu, K.; Xie, L.; Zhou, X.; Song, Z.; Gao, Y.; Sun, Z.; Patel, J. S.; Zhai, C.; Yuan, K. Y.; Collier, T. L.; Ran, C.; Collin, L.; Haider, A.; Grether, U.; Wittwer, M. B.; Cravatt, B. F.; Zhang, M.-R. and Liang, S. H. “Radiosynthesis and Evaluation of Novel 18F Labeled PET Ligands for Imaging Monoacylglycerol Lipase”, European Journal of Medicinal Chemistry, 2025, 117246. Link: https://www.sciencedirect.com/science/article/abs/pii/S022352342500011X
|
|
194. Rong, J. and Liang, S. H. “Novel 5,6-fused and 6,6-fused bicyclic compounds as 15-prostaglandin dehydrogenase modulators”, ACS Medicinal Chemistry Letters, 2025, ASAP. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00010 |
|
193. Hu, Q.-L. and Liang, S. H. “Novel Cyclic Peptides Inhibiting Tumor Necrosis Factor Receptor 1 Activity”, ACS Medicinal Chemistry Letters, 2025, ASAP. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00011 |
|
192. Zhao, T. and Liang, S. H. “Novel Pyrimidinyl Sulfonamide Derivatives as GPR17 Modulators”, ACS Medicinal Chemistry Letters, 2025, accepted. |
|
191. Xin, Z. and Liang, S. H. “Hydroquinazoline Derivatives as Novel Natriuretic Peptide Receptor 1 (NPR1) Activators”, ACS Medicinal Chemistry Letters, 2025, ASAP. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00013 |
|
190. Song, Z. and Liang, S. H. “Identification of Phosphodiesterase-7 Inhibitors with Spiro[[1,3]Oxazolo[5,4-f]Quinazoline-9,1′-Cyclohexan]-7-One Scaffold for the Treatment of Chronic Fatigue”, ACS Medicinal Chemistry Letters, 2025, accepted. |
|
189. Tan, Z.; Nie, B.; Wu, H.; Li, B.; Shang, J.; Zhang, T.; Xiao, Z.; Dong, C.; Zeng, C.; Wu, B.; Hou, L.; Guo, B.; Cheng, Y.; Gong, J.; Ye, W.; Xu, L.; Li, Y.; Li, X.; Liang, S. H.; Shan, B.; Xu, H.; Wang, L. “Brain development during the lifespan of cynomolgus monkeys”, NeuroImage, 2025, 305, 120952. Link: https://pubmed.ncbi.nlm.nih.gov/39662788/
|
|
188. Li, Y. and Liang, S. H. “Novel Piperazine Derivatives as Selective Antagonists of GluN2B-containing NMDARs under Acidic pH Conditions”, ACS Medicinal Chemistry Letters, 2025, accepted. |
|
187. Hu, Q.-L. and Liang, S. H. “Cyclic Peptides Targeting Granzyme B: Potential Applications as PET Imaging Agents”, ACS Medicinal Chemistry Letters, 2025, ASAP. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.4c00608 |
|
186. Zhao, T. and Liang, S. H. “Novel Tricyclic KRAS Inhibitors for the Treatment of Cancer”, ACS Medicinal Chemistry Letters, 2025, ASAP. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.4c00609 |
|
185. Li, Y. and Liang, S. H. “Novel Heterocyclic Piperazine Amide Derivatives as Alpha-synuclein PET Ligands for Diagnosis of Parkinson’s Disease”, ACS Medicinal Chemistry Letters, 2025, ASAP. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.4c00606 |
|
184. Song, Z. and Liang, S. H. “Imaging Alpha-synuclein with Novel 5H-Imidazo[1,5-b][1,2,4]triazole Radioligands for the Diagnosis of Parkinson’s Disease”, ACS Medicinal Chemistry Letters, 2025, ASAP. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.4c00607 |
